文献速递结核与非结核分枝杆菌艾滋病与性传播感染

结核预防研究中复合母婴结局指标的应用

Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women.
PubMed 文献 · Clin Infect Dis · 2021-01-01

研究通过两阶段德尔菲调查构建优先考虑母婴事件的复合结局指标,并利用TB APPRISE试验数据评估孕期启动结核预防性治疗的利弊。

要点

  • 复合母婴结局指标可用于评估孕期结核预防性治疗的风险获益。
  • 使用奈韦拉平者产前启动预防性治疗结局更差。
  • 使用依非韦伦者产前与产后启动预防性治疗无差异。

核心结论

  • 对于健康人群的结核预防性治疗,利益相关方认为预防不良事件最为重要。
  • 在高结核负担地区感染HIV的孕妇中,决定结核预防性治疗启动时机时应考虑产前抗逆转录病毒方案。

研究设计与样本

  • 通过两阶段德尔菲调查构建复合结局指标,由利益相关方按0(最好)至100(最差)评分。
  • 利用TB APPRISE试验数据评估孕期启动异烟肼预防性治疗的时机,该试验随机分配产前与产后启动。

主要发现

  • 复合结局评分系统将母婴配对结局分为8组,各组由利益相关方赋予相同中位评分。
  • 母婴结核与非严重不良妊娠结局被赋予相似评分。
  • 产前启动组与产后启动组的复合结局平均(SD)评分分别为43.7(33.0)和41.2(33.7)。
  • 基线抗逆转录病毒方案存在修饰效应(P = .049)。

临床怎么用

  • 在高结核负担地区感染HIV的孕妇中,选择结核预防性治疗启动时机时应评估产前抗逆转录病毒方案。
  • 使用奈韦拉平者可能倾向于产后启动结核预防性治疗以减少不良结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis (TB-)-preventive therapy (TPT) among pregnant women reduces risk of TB in mothers and infants, but timing of initiation should consider potential adverse effects. We propose an analytical approach to evaluate the risk-benefit of interventions. METHODS: A novel outcome measure that prioritizes maternal and infant events was developed with a 2-stage Delphi survey, where a panel of stakeholders assigned scores from 0 (best) to 100 (worst) based on perceived desirability. Using data from TB APPRISE, a trial among pregnant women living with human immunodeficiency virus (WLWH) that randomized the timing of initiation of isoniazid, antepartum versus postpartum, was evaluated. RESULTS: The composite outcome scoring/ranking system categorized mother-infant paired outcomes into 8 groups assigned identical median scores by stakeholders. Maternal/infant TB and nonsevere adverse pregnancy outcomes were assigned similar scores. Mean (SD) composite outcome scores were 43.7 (33.0) and 41.2 (33.7) in the antepartum and postpartum TPT initiation arms, respectively. However, a modifying effect of baseline antiretroviral regimen was detected (P = .049). When women received nevirapine, composite scores were higher (worse outcomes) in the antepartum versus postpartum arms (adjusted difference, 14.3; 95% confidence interval [CI], 2.4-26.2; P = .02), whereas when women received efavirenz there was no difference by timing of TPT (adjusted difference, .62; 95% CI, -3.2-6.2; P = .53). CONCLUSIONS: For TPT, when used by otherwise healthy persons, preventing adverse events is paramount from the perspective of stakeholders. Among pregnant WLWH in high-TB-burden regions, it is important to consider the antepartum antiretroviral regimen taken when deciding when to initiate TPT. Clinical Trials Registration. NCT01494038 (IMPAACT P1078).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Montepiedra G, Kim S, Weinberg A, et al. Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women. Clin Infect Dis. 2021. PMID: 33146706. doi:10.1093/cid/ciaa1674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。